4.7 Article

Predictive and Experimental Immunogenicity of Burkholderia Collagen-like Protein 8-Derived Antigens

Journal

VACCINES
Volume 9, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/vaccines9111219

Keywords

vaccine; Bucl8; subunit vaccine; antigenicity; immunogenicity

Funding

  1. Vaccine Development Center at WVU-HSC
  2. Research Challenge Grant from the Division of Science and Research, WV Higher Education Policy Commission [HEPC.dsr.18.6]
  3. Broad Agency Announcement (BAA) Research and Development Enterprise, Basic and Applied Sciences Directorate, Basic Research for Combating Weapons of Mass Destruction. (C-WMD) [HDTRA1-14-24-FRCWMD, HDTRA1035955001]
  4. U.S. Defense Threat Reduction Agency (DTRA)
  5. US Defense Threat Reduction Agency (DTRA) project award [CB10207]
  6. Marie Sklodowska-Curie Action BactiVaxAnti-Bacterial Innovative Vaccines [GA 860325]
  7. COST Action ENOVA-European Network of Vaccine Adjuvants
  8. National Institutes of Health equipment [S10OD016165]
  9. Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P30GM121322, P20GM103434]

Ask authors/readers for more resources

This study examined the immune response to a vaccine formulated with antigens derived from the outer membrane protein Bucl8 in Burkholderia pseudomallei and found that synthetic loop peptides elicited a stronger and more consistent antibody response compared to recombinant protein antigens, resulting in a TH2-skewed response.
Burkholderia pseudomallei is an infectious bacterium of clinical and biodefense concern, and is the causative agent of melioidosis. The mortality rate can reach up to 50% and affects 165,000 people per year; however, there is currently no vaccine available. In this study, we examine the antigen-specific immune response to a vaccine formulated with antigens derived from an outer membrane protein in B. pseudomallei, Bucl8. Here, we employed a number of bioinformatic tools to predict Bucl8-derived epitopes that are non-allergenic and non-toxic, but would elicit an immune response. From these data, we formulated a vaccine based on two extracellular components of Bucl8, the beta-barrel loops and extended collagen and non-collagen domains. Outbred CD-1 mice were immunized with vaccine formulations-composed of recombinant proteins or conjugated synthetic peptides with adjuvant-to assess the antigen-specific immune responses in mouse sera and lymphoid organs. We found that mice vaccinated with either Bucl8-derived components generated a robust TH2-skewed antibody response when antigen was combined with the adjuvant AddaVax, while the TH1 response was limited. Mice immunized with synthetic loop peptides had a stronger, more consistent antibody response than recombinant protein antigens, based on higher IgG titers and recognition of bacteria. We then compared peptide-based vaccines in an established C57BL/6 inbred mouse model and observed a similar TH2-skewed response. The resulting formulations will be applied in future studies examining the protection of Bucl8-derived vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available